Term
Astelin
Category and Indication/Dx |
|
Definition
Nasal Antihistamine
DX: Allergic Rhinitis, Vasomotor Rhinitis |
|
|
Term
|
Definition
| 12 years or older: As adults; 1-2 sprays per nostril BID |
|
|
Term
Astelin 0.1% (125mcg/spray)
Pediatric dose |
|
Definition
<5 years: Safety and efficacy not established
5-11 years: 1 spray per nostril BID |
|
|
Term
Astepro
Category and Indication/Dx |
|
Definition
Nasal Antihistamine
DX: Allergic Rhinitis, Vasomotor Rhinitis |
|
|
Term
|
Definition
12 years or older:
As adults; 0.1% or 0.15%: 1-2 sprays per nostril BID,
OR 0.15%: 2 sprays per nostril q Day |
|
|
Term
Astepro 0.15% (187.6mcg/spray)
Pediatric dose |
|
Definition
| <12 years: Safety and efficacy not established |
|
|
Term
Atrovent
Category and Indication/Dx |
|
Definition
Anticholinergic drying agent
Dx: Vasomotor Rhinitis |
|
|
Term
Atrovent Nasal Spray 0.03% and 0.06%
Adult Dose |
|
Definition
Allergic/nonallergic rhinitis: 2 sprays (0.03%) per nostril BID/TID
Rhinitis due to common cold: 2 sprays (0.06%) per nostril TID/QID |
|
|
Term
Atrovent Nasal Spray 0.03% and 0.06%
Pediatric Dose |
|
Definition
<5 years: Safety & efficacy not established
5-12 years: 2 sprays (0.06%) in each nostril TID
>12 years: 2 sprays (0.06%) in each nostril TID/QID |
|
|
Term
|
Definition
<2 years: Safety and efficacy not established
2 years or older: 1 spray each nostril TID-QID, may increase to 6 times/day; may take 2-4 weeks before symptomatic relief observed
For best results, initiate 1-2 weeks before contact with allergens |
|
|
Term
Patanase
Category and Indication/Dx |
|
Definition
Nasal Antihistamine
DX: Allergic Rhinitis, Vasomotor Rhinitis |
|
|
Term
Patanase 6%, 665mcg/spray
Adult dose |
|
Definition
|
|
Term
Patanase 6%, 665mcg/spray
Pediatric dose |
|
Definition
<6 years: Safety and efficacy not established
6-11 years: 1 spray per nostril BID |
|
|
Term
Beconase AQ
Category and Indication/Dx |
|
Definition
Nasal Steroid
Antiinflammatory
DX: Allergic Rhinitis, Vasomotor Rhinitis |
|
|
Term
Beconase AQ 42 mcg/spray
Adult dose |
|
Definition
| 1-2 sprays/nostril BID (total dose: 168-336 mcg/day) |
|
|
Term
Beconase AQ 42 mcg/spray
Pediatric dose |
|
Definition
<6 years old: Safety and efficacy not established
6-11 years old: 1 spray/nostril BID (168 mcg/day); may increase to 2 sprays/nostril (336 mcg/day) in patients not adequately responding or those with more severe symptoms; decrease dose to 1 spray/nostril BID once adequate control achieved |
|
|
Term
Omnaris
Category and Indication/Dx |
|
Definition
Nasal Steroid
Antiinflammatory
DX: Allergic Rhinitis, Vasomotor Rhinitis |
|
|
Term
Omnaris 50mcg/actuation
Adult dose |
|
Definition
|
|
Term
Omnaris 50mcg/actuation
Pediatric dose |
|
Definition
<6 years: Safety and efficacy not established
6 years or older: As adults; 2 sprays/nostril qDay (ie, 200 mcg/day) |
|
|
Term
Flonase
Category and Indication/Dx |
|
Definition
Nasal Steroid
Antiinflammatory
DX: Allergic Rhinitis, Vasomotor Rhinitis |
|
|
Term
Veramyst
Category and Indication/Dx |
|
Definition
Nasal Steroid
Antiinflammatory
DX: Allergic Rhinitis, Vasomotor Rhinitis |
|
|
Term
Flonase, Veramyst (fluticasone)50mcg/spray
Adult dose |
|
Definition
2 sprays in each nostril qDay (ie, 200 mcg/day)
After first few days, patient may reduce dosage to 1 spray in each nostril qDay (ie, 100 mcg/day) |
|
|
Term
Flonase, Veramyst (fluticasone)50mcg/spray
Pediatric dose |
|
Definition
| >4 years: 1 spray (50 mcg) in each nostril qDay; may increase up to 2 sprays/nostril qDay |
|
|
Term
Nasacort AQ
Category and Indication/Dx |
|
Definition
Nasal Steroid
Antiinflammatory
DX: Allergic Rhinitis, Vasomotor Rhinitis |
|
|
Term
Nasacort AQ triamcinolone 55mcg/spray
Adult dosing |
|
Definition
| 220 mcg qDay as 2 sprays/nostril qDay |
|
|
Term
Nasonex
Category and Indication/Dx |
|
Definition
Nasal Steroid
Antiinflammatory
DX: Allergic Rhinitis, Vasomotor Rhinitis |
|
|
Term
Nasonex 50mcg/spray
Adult dosing |
|
Definition
| 2 sprays (100 mcg) in each nostril qDay |
|
|
Term
Nasonex 50mcg/spray
Pediatric dosing |
|
Definition
<2 years: Safety and efficacy not established
2-11 years: 1 spray (50 mcg) in each nostril qDay |
|
|
Term
Nasacort AQ triamcinolone 55mcg/spray
Pediatric dosing |
|
Definition
<2 years: Safety and efficacy not established
2-5 years: 110 mcg/day as 1 spray/nostril qDay
6-11 years: 110 mcg/day as 1 spray/nostril qDay; may increase to 2 sprays/nostril qDay (ie, 220 mcg/day) |
|
|
Term
Mucinex
Category and Indication/Dx |
|
Definition
Expectorant/Mucous thinner
DX: Respiratory infections |
|
|
Term
|
Definition
| Extended Release: 1-2 tablets (600-1200 mg) PO q12hr; not to exceed 4 tablets/24 hr (2.4 g/day) |
|
|
Term
Mucinex D
Regular Strength: 600mg + 60mg pseudoephedrine
Maximum Strength: 1200mg + 120mg pseud |
|
Definition
| Expectorant/Mucous thinner + decongestant |
|
|
Term
|
Definition
1 maximum strength or 1-2 regular bid .
Do not take after 6 pm to avoid insomnia
Avoid with HTN, arrythmia, insomnia |
|
|
Term
Mucinex DM
Regular Strength: 600mg + 30mg DM
Maximum Strength: 1200mg + 60mg DM |
|
Definition
| Expectorant/Mucous thinner + cough suppressant (DextroMethorphan...DM) |
|
|
Term
|
Definition
| 1 maximum strength or 1-2 regular bid |
|
|
Term
Tessalon Perles
Category and Indication/Dx |
|
Definition
|
|
Term
Tessalon Perles 100 mg or 200 mg
Adult Dosing |
|
Definition
100 mg PO TID; 600 mg/day maximum
Swallow whole; do not chew |
|
|
Term
Tessalon Perles 100 mg or 200 mg
Pediatric Dosing |
|
Definition
<10 years old: Safety & efficacy not established
>10 years old: As in adults
Swallow whole; do not chew |
|
|
Term
Singulair (montelukast)
Category and Indication/Dx |
|
Definition
Oral anti inflammatory (non steroid)
Asthma "Controller" medication
Nasal allergy relief |
|
|
Term
Singulair (montelukast)
Adult dosing |
|
Definition
| 10 mg PO q Evening (use 10 mg tablet) |
|
|
Term
Singulair (montelukast) chewable 4mg,5mg
oral granules 4mg/packet
Pediatric dosing |
|
Definition
<12 months: Safety and efficacy not established
12-24 months: 4 mg (granules) PO qEvening
2-5 years: 4 mg (chewable tablet or granules) PO qEvening
6-14 years: 5 mg (chewable tablet) PO qEvening
15 years or older: 10 mg (conventional tablet) PO qEvening |
|
|
